AOAH

Across TCGA pan-cancer cohorts, AOAH Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AOAH data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher AOAH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AOAH expression acts as an unfavorable survival marker.

BRCA, HNSC, and MESO are the cancer types where AOAH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	II,III,IV	0.777	0.958	.001	22	view →
HNSC	OS	Median	II,III,IV	0.130	0.756	<.001	22	view →
MESO	OS	Median	All	0.130	0.557	.019	18	view →
GBM	DFS	Median	All	0.077	0.258	.019	6	view →
LIHC	DFS	Median	II,III,IV	0.070	0.429	.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AOAH–BRCA (OS)

Open the BRCA breakdown →